Baxter International Inc. (BAX - Analyst Report) declared the commercial launch of HEMOPATCH Sealing Hemostat, following CE mark approval in Europe. The development of this new collagen-based hemostatic device showcases the strong expertise of the company in collagen, internal coagulation processes and PEG (polyethylene glycol) technology platforms.
The HEMOPATCH is an important addition to Baxter’s BioSurgery product portfolio, which consists of a range of biological and synthetic products and delivery devices used for hemostasis, tissue sealing, adhesion reduction, hard tissue regeneration, as well as soft tissue repair and microsurgery products.
Hemostasis is a physiological process which stops bleeding resulting from a cut or injury. Bleeding in surgical procedures is a major problem encountered by all surgeons. Complications from excessive bleeding may include blood loss, tissue damage, infection and excessive scarring. If uncontrolled, it can even turn out to be life-threatening.
Baxter’s HEMOPATCH will provide a unique solution to this problem. It is a resorbable hemostatic device effectively designed to stop bleeding in surgical situations where other conventional methods often fail.
The thin, soft and flexible collagen pad allows surgeons to attain rapid hemostasis, as it firmly adheres to the bleeding tissue surface. Further, the specially-formulated porous collagen matrix, covered on one side with a thin protein bonding layer, known as NHS-PEG, helps to seal off the bleeding surface, initiating the body’s own clotting process.
The new surgical tool promises to be a boon for surgeons. It is quick and effective, requires zero preparation time, and can be applied to varied surgical settings. Preclinical testing has also guaranteed the product’s hemostatic performance, biocompatibility, and safety profile.
Baxter plans to launch the new bio surgical product in other countries as well.
Recently it launched HyQvia, a replacement therapy for adults with primary and secondary immunodeficiencies, in Germany. Additional product launches in the European markets are also on the cards.
Baxter currently carries a Zacks Rank #3 (Hold). Other stocks that are worth a look include Bio-Rad Laboratories, Inc. (BIO - Snapshot Report) and INSYS Therapeutics, Inc. (INSY - Snapshot Report), each carrying a Zacks Rank #1 (Strong Buy) and Boston Scientific Corp. (BSX - Analyst Report) carrying a Zacks Rank #2 (Buy).